The University of Southampton
University of Southampton Institutional Repository

Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series

Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series
Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series
Introduction
Delirium affects up to 80% of patients admitted to intensive care units (ICUs) and contributes to increased morbidity and mortality. Haloperidol is the gold standard for treatment, although quetiapine has been successfully used in the management of delirium.

Methods
We conducted a retrospective study of patients admitted to the ICU between February 2008 and May 2010 who were prescribed quetiapine by the attending clinician. Data collected included demographics, history of drug and/or alcohol dependence, ICU and hospital length of stay, length of mechanical ventilation and the duration of treatment with sedatives and medications for delirium. The daily dose of quetiapine was recorded. Hyperactive or mixed delirium was identified by a validated chart review and a Richmond Agitation Sedation Scale (RASS) score persistently greater than 1 for 48 hours despite therapy.

Results
Seventeen patients were included. Delirium onset occurred after a median of five days. Patients were being given at least four agents for delirium prior to the introduction of quetiapine, and they had a median RASS score of 3. Quetiapine was initiated at a 25 mg daily dose and titrated to a median daily dose of 50 mg. The median duration of delirium prior to quetiapine therapy was 15 days. Quetiapine commencement was associated with a reduction in the need for other medications (within 0 to 6 days) and resolution of delirium within a median of four days. Adverse events included somnolence and transient hypotension.

Conclusions
This case series provides an initial effort to explore a possible role for quetiapine in the management of refractory hyperactive and mixed ICU delirium.
1364-8535
Wan, R.Y.Y.
5a3dcc7d-a4cc-4478-b020-e97fbef4352e
Kasliwal, M.M.
1717ea1f-f68e-4fa4-b6b1-483ffa0ea656
McKenzie, C.A.
ec344dee-5777-49c5-970e-6326e82c9f8c
Barrett, N.A.
de6ecdb7-5948-4ed1-a12f-ff0f417e4721
Wan, R.Y.Y.
5a3dcc7d-a4cc-4478-b020-e97fbef4352e
Kasliwal, M.M.
1717ea1f-f68e-4fa4-b6b1-483ffa0ea656
McKenzie, C.A.
ec344dee-5777-49c5-970e-6326e82c9f8c
Barrett, N.A.
de6ecdb7-5948-4ed1-a12f-ff0f417e4721

Wan, R.Y.Y., Kasliwal, M.M., McKenzie, C.A. and Barrett, N.A. (2011) Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series. Critical Care, 15, [R159]. (doi:10.1186/cc10294).

Record type: Article

Abstract

Introduction
Delirium affects up to 80% of patients admitted to intensive care units (ICUs) and contributes to increased morbidity and mortality. Haloperidol is the gold standard for treatment, although quetiapine has been successfully used in the management of delirium.

Methods
We conducted a retrospective study of patients admitted to the ICU between February 2008 and May 2010 who were prescribed quetiapine by the attending clinician. Data collected included demographics, history of drug and/or alcohol dependence, ICU and hospital length of stay, length of mechanical ventilation and the duration of treatment with sedatives and medications for delirium. The daily dose of quetiapine was recorded. Hyperactive or mixed delirium was identified by a validated chart review and a Richmond Agitation Sedation Scale (RASS) score persistently greater than 1 for 48 hours despite therapy.

Results
Seventeen patients were included. Delirium onset occurred after a median of five days. Patients were being given at least four agents for delirium prior to the introduction of quetiapine, and they had a median RASS score of 3. Quetiapine was initiated at a 25 mg daily dose and titrated to a median daily dose of 50 mg. The median duration of delirium prior to quetiapine therapy was 15 days. Quetiapine commencement was associated with a reduction in the need for other medications (within 0 to 6 days) and resolution of delirium within a median of four days. Adverse events included somnolence and transient hypotension.

Conclusions
This case series provides an initial effort to explore a possible role for quetiapine in the management of refractory hyperactive and mixed ICU delirium.

This record has no associated files available for download.

More information

Published date: 2011

Identifiers

Local EPrints ID: 480334
URI: http://eprints.soton.ac.uk/id/eprint/480334
ISSN: 1364-8535
PURE UUID: d428df8d-6be7-4613-a1c2-f8509a404338
ORCID for C.A. McKenzie: ORCID iD orcid.org/0000-0002-5190-9711

Catalogue record

Date deposited: 01 Aug 2023 17:23
Last modified: 17 Mar 2024 04:23

Export record

Altmetrics

Contributors

Author: R.Y.Y. Wan
Author: M.M. Kasliwal
Author: C.A. McKenzie ORCID iD
Author: N.A. Barrett

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×